Press release - June 6th, 2013

Cerbomed at the INS 11th World Congress in Berlin.

ERLANGEN/BERLIN, Germany, June 6th, 2013 – Between June 9th and 12th, 2013, the German medical device company cerbomed GmbH will present another therapy option for people suffering from hard-to-treat neurological and psychiatric diseases at the 11th world congress of the International Neuromodulation Society in Berlin: transcutaneous Vagus Nerve Stimulation (t-VNS).

About t-VNS
The t-VNS offers a therapy option for patients suffering from epilepsies, depression or pain.
This therapy uses a branch of the vagus nerve that is located closely under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses.
The t-VNS therapy is carried out autonomously by the patients and is easy to integrate into the daily routine. The advantages of t-VNS:
No surgery, no hospitalization, minor side effects. 

About cerbomed
Cerbomed GmbH is an innovative medical device company located in Erlangen, Germany, that focuses on neuromodulation. The company, founded in 2005, focuses on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard-to-treat neurological and psychiatric illnesses.

The transcutaneous Vagus Nerve Stimulation received the European clearance (CE mark) for the treatment of epilepsies, depression and pain.
Currently two clinical studies are carried out regarding the effectiveness of t-VNS in patients with drug-resistant epilepsy and chronic migraine.

In September 2012 cerbomed entered into a strategic partnership with Cyberonics, Inc., the global market leader in vagus nerve stimulation.

The therapy device NEMOS is available for treating epilepsies in Germany and Austria, and in Italy from March 2013. Forthcoming cooperations with other distributors should make NEMOS available to epilepsy patients in Great Britain, France and Spain.

pdf Download Article


Please note: NEMOS® is not cleared or approved for use in the U.S.